ArticleProteomics2011
Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.
Article in Proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Solvent Interaction Analysis: A New Lens for Protein Structure and Diagnostics.International journal of molecular sciences · 2026Review
- Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.Proteomes · 2017Review
- Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators.Analytical chemistry · 2017Article
- Development of quantitative mass spectrometric immunoassay for serum amyloid A.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2016Article
- Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms.Bioanalysis · 2016Review
- Transthyretin variants with improved inhibition of β-amyloid aggregation.Protein engineering, design & selection : PEDS · 2016Article
- Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.Proteomes · 2016Review
- Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms.Methods (San Diego, Calif.) · 2015Article
- Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants.Journal of proteomics · 2015Article
- Delineation of concentration ranges and longitudinal changes of human plasma protein variants.PloS one · 2014Article
- Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.Proteomics. Clinical applications · 2013Review
- Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.Journal of cancer research and clinical oncology · 2013Article
- Efficient sample preparation in immuno-matrix-assisted laser desorption/ionization mass spectrometry using acoustic trapping.Biomicrofluidics · 2013Article
- Advantageous uses of mass spectrometry for the quantification of proteins.International journal of proteomics · 2013Article
- Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.Molecular & cellular proteomics : MCP · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Transthyretin (TTR, or prealbumin) is a tetrameric protein found in plasma and cerebrospinal fluid. Its major role is to transport thyroid hormones (thyroxin-T4) and retinol (through association with retinol-binding protein). TTR has been studied extensively due to the great number of point mutations that result in sequence heterogeneity. Many of these variants are associated with pathological conditions that result in extracellular deposition of amyloid fibers in tissues. In this work, we have developed a rapid mass spectrometric immunoassay for determination and quantification of TTR and its variants from human serum and plasma samples. The assay was fully characterized in terms of its precision, linearity and recovery characteristics. The new assay was also compared with a conventional TTR ELISA. Furthermore, we have applied the optimized method to analyze TTR and its modifications in 44 human plasma samples, and in the process optimized a method for TTR proteolytic digestion and identification of point mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.